Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Top Page
Acumen Pharmaceuticals
(NASDAQ:ABOS)
41Neutral
Positive Factors
Clinical Trials
Acumen Pharmaceuticals has completed enrollment for the ALTITUDE AD trial, showing strong interest in their differentiated anti-Abeta immunotherapy.
Financial Metrics
The company's cash runway is projected to support key catalysts through 2025 and 2026, potentially increasing investor interest.
Product Differentiation
Sabirnetug is seen as having potential as a best-in-class alternative to existing Alzheimer’s treatments, such as Leqembi and Kisunla.
Negative Factors
Product Safety
The subQ formulation of sabirnetug, although showing a decent safety profile, has a very high proportion of mild injection site reactions at around 62.5%.
Stock Valuation
The reevaluation of operational expense assumptions has led to a reduction in the price target from $15 to $11.
Acumen Pharmaceuticals (ABOS) vs. S&P 500 (SPY)
Market Cap
$59.23M
Dividend YieldN/A
Average Volume (3M)224.37K
Price to Earnings (P/E)―
Beta (1Y)2.28
Revenue GrowthN/A
EPS Growth-57.45%
CountryUS
Employees61
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.70
Shares Outstanding60,573,425
10 Day Avg. Volume256,456
30 Day Avg. Volume224,374
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14419.15
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.33Price Target Upside758.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Acumen Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
How the Company Makes MoneyAcumen Pharmaceuticals generates revenue primarily through funding from investors, partnerships, and collaborations rather than traditional product sales, as it is still in the clinical trial phase. The company relies on strategic alliances with pharmaceutical companies, research institutions, and government grants to support its research and development activities. Additionally, Acumen may receive milestone payments and royalties from potential future licensing agreements for its drug candidates, contingent upon successful clinical development and regulatory approval.
Acumen Pharmaceuticals Financial Statement Overview
Summary
Acumen Pharmaceuticals faces significant financial challenges with no revenue generation and mounting losses. The balance sheet is stable with no debt, but declining assets could pose future liquidity risks. Cash flow issues are prominent, with heavy reliance on financing activities to support operations.Income Statement
Acumen Pharmaceuticals' income statement shows a persistent lack of revenue generation, with total revenues standing at zero for the past four years. The company has been experiencing substantial net losses, with a notable increase in net loss from $73.2 million in 2020 to $102.3 million in 2024. The absence of revenue combined with increasing operating losses highlights significant challenges in achieving profitability.15
Very Negative
Balance Sheet
The balance sheet reflects a stable equity base, with stockholders' equity exceeding liabilities, indicating a low risk of insolvency. However, the company has seen a decline in total assets from $310.1 million in 2023 to $239 million in 2024. The absence of debt provides financial flexibility, but the consistent decrease in asset base may indicate potential liquidity concerns.45
Neutral
Cash Flow
The cash flow statement reveals negative free cash flow over the years, with an increasing deficit from $43 million in 2023 to $86 million in 2024. Operating cash flow remains negative, highlighting ongoing challenges in generating cash from operations. Financing activities have been a critical source of cash, but reliance on external financing may not be sustainable long-term.30
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 290.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M |
| Gross Profit | |||||
| 162.00K | 0.00 | -42.32M | -169.00K | -4.00K | 1.43M |
| EBIT | |||||
| -92.91M | -114.02M | -61.14M | -45.24M | 61.57M | -7.91M |
| EBITDA | |||||
| -75.48M | -114.02M | -51.61M | -42.69M | 61.58M | 587.00K |
| Net Income Common Stockholders | |||||
| -81.67M | -102.33M | -52.37M | -40.48M | -181.68M | -7.32M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 6.55M | 171.56M | 243.52M | 177.60M | 194.24M | 43.78M |
| Total Assets | |||||
| 0.00 | 238.99M | 310.13M | 196.59M | 230.33M | 44.43M |
| Total Debt | |||||
| 0.00 | 0.00 | 28.49M | 105.00K | 0.00 | 0.00 |
| Net Debt | |||||
| 6.55M | -35.63M | -38.40M | -130.00M | -122.16M | -43.78M |
| Total Liabilities | |||||
| 0.00 | 57.18M | 43.15M | 7.81M | 5.15M | 63.02M |
| Stockholders Equity | |||||
| 5.98M | 181.82M | 266.97M | 188.78M | 225.18M | -18.59M |
| Cash Flow | Free Cash Flow | ||||
| -67.34M | -86.23M | -43.09M | -35.31M | -18.00M | -7.45M |
| Operating Cash Flow | |||||
| -67.31M | -86.22M | -43.06M | -35.15M | -17.96M | -7.45M |
| Investing Cash Flow | |||||
| -30.44M | 48.03M | -171.67M | 39.19M | -104.12M | 0.00 |
| Financing Cash Flow | |||||
| 36.07M | 6.93M | 151.75M | 3.91M | 200.47M | 44.67M |
Acumen Pharmaceuticals Technical Analysis
Negative
0.97
Price Trends
1.29
Negative
1.65
Negative
2.17
Negative
Market Momentum
-0.06
Positive
34.70
Neutral
11.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Negative. The current price of 0.97 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.29, and below the 200-day MA of 2.17, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 34.70 is Neutral, neither overbought nor oversold. The STOCH value of 11.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABOS.
Acumen Pharmaceuticals Risk Analysis
Acumen Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. Acumen Pharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acumen Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $17.45B | 10.20 | 10.36% | ― | -1.60% | 39.71% | |
49 Neutral | $166.70M | ― | -119.83% | ― | -90.97% | -27.47% | |
48 Neutral | $6.27B | 1.17 | -48.19% | 2.68% | 17.28% | 1.24% | |
47 Neutral | $583.48M | ― | -23.34% | ― | 47.92% | 17.84% | |
42 Neutral | $62.80M | ― | -17.19% | ― | ― | 81.00% | |
41 Neutral | $59.23M | ― | -45.60% | ― | ― | -57.45% | |
38 Underperform | $24.16M | ― | -3159.09% | ― | ― | 68.75% |
* Healthcare Sector Average
Performance Comparison
ABOS
Acumen Pharmaceuticals
0.97
-2.87
-74.74%
BIIB
Biogen
114.05
-92.47
-44.78%
SAVA
Cassava Sciences
1.19
-24.21
-95.31%
PRTA
Prothena
10.48
-13.06
-55.48%
INMB
Inmune Bio
6.84
-3.72
-35.23%
ANVS
Annovis Bio
1.22
-10.27
-89.38%
Acumen Pharmaceuticals Earnings Call Summary
Earnings Call Date: Mar 27, 2025 | % Change Since: -16.38% | Next Earnings Date: May 20, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in clinical trials and financial stability but also noted substantial operational losses and high instances of mild injection site reactions in a new formulation study.Highlights
Completion of ALTITUDE AD Phase 2 Enrollment
Acumen Pharma successfully completed enrollment of 542 participants in the ALTITUDE AD Phase 2 study ahead of schedule, demonstrating the team's ability to exceed enrollment goals.
Subcutaneous Formulation Development
The Phase 1 study investigating subcutaneous administration of sabirnetug was completed. Results showed it was well-tolerated, with systemic exposure supporting continued development, providing important optionality for patients.
Financial Position
Acumen ended 2024 with $231.5 million in cash and marketable securities, expected to support clinical and operational activities into the first half of 2027.
Lowlights
Loss from Operations
Acumen reported a loss from operations of $114 million and a net loss of $102.3 million for the year, highlighting financial challenges.
High Injection Site Reactions in Subcutaneous Study
The Phase 1 study of the subcutaneous formulation showed a 62.5% rate of injection site reactions, although they were all mild.
Company Guidance
During the Fiscal Year 2024 conference call, Acumen Pharma provided several key metrics and updates on their Alzheimer's drug development. The company's Phase 2 clinical trial, ALTITUDE AD, successfully completed enrollment with 542 participants, ahead of schedule, marking a significant milestone. This trial focuses on evaluating the efficacy of sabirnetug, with a primary endpoint of change from baseline to 18 months on the Integrated Alzheimer's Disease Rating Scale (iADRS). The trial also includes secondary measures such as the CDR Sum of Boxes and various biomarkers. Financially, Acumen ended 2024 with $231.5 million in cash and securities, expecting this to fund operations into the first half of 2027. R&D expenses rose to $93.8 million, primarily due to the ALTITUDE AD trial, while G&A expenses remained steady at $20.2 million, culminating in a net loss of $102.3 million for the year. The company anticipates sharing top-line results from ALTITUDE AD in late 2026 and is also advancing a subcutaneous formulation of sabirnetug following promising Phase 1 results.Acumen Pharmaceuticals Corporate Events
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Acumen Pharmaceuticals Completes Enrollment for Phase 2 Study
Neutral
Mar 27, 2025
On March 27, 2025, Acumen Pharmaceuticals announced the completion of enrollment for its ALTITUDE-AD Phase 2 study, investigating sabirnetug for early Alzheimer’s disease, with topline results expected in late 2026. The company reported a cash balance of $231.5 million as of December 31, 2024, projected to support operations into the first half of 2027, despite a net loss of $102.3 million for 2024 due to increased R&D expenses.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.